The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage II/III gastric cancer
- 273 Downloads
Recently, lymphocyte to monocyte ratio (LMR) has been reported to be associated with clinical outcomes in some types of cancer but has not been explored in gastric cancer. In this study, we analyzed the association between LMR and clinical outcomes in stage II/III gastric cancer patients. Preoperative LMR calculated from peripheral lymphocyte and monocyte with corresponding clinical features from 426 stage II/III gastric cancer patients was noted. Kaplan–Meier method and Cox regression model were applied for overall survival (OS) and recurrence-free survival (RFS). Related with smaller tumor size (p < 0.001), increased LMR could predict better OS [hazard ratio (HR), 0.688; 95 % confidence interval (CI), 0.521–0.908, p = 0.008] and was borderline significantly associated with better RFS (HR, 0.775; 95 % CI, 0.592–1.01, p = 0.06) in stage II/III gastric cancer patients through multivariable analysis. Subgroup analyses revealed that except stage III patients for RFS which yielded borderline significance (p = 0.052), lower LMR was associated with poor clinical outcomes for patients regardless of different stages or whether the patients received adjuvant chemotherapy. The elevated preoperative LMR level was a significant favorable factor in the prognosis of stage II/III gastric cancer patients, especially for those with stage II. However, further validation of our findings is warranted.
KeywordsLMR Gastric cancer Prognosis
This study was supported by the National Natural Science Foundation of China (Grant number: 81171908).
Conflicts of interest
- 1.Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol WJG. 2006;12:354–62.Google Scholar
- 4.Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9.PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Cho IR, Park JC, Park CH, Jo JH, Lee HJ, Kim S, Shim CN, Lee H, Shin SK, Lee SK, Lee YC: Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer. 2014. doi: 10.1007/s10120-013-0330-2.
- 17.Penta R, De Falco M, Iaquinto G, De Luca A. Helicobacter pylori and gastric epithelial cells: from gastritis to cancer. J Exp Clin Cancer Res CR. 2005;24:337–45.Google Scholar